Partnership Enhances Development Capacity of Tevogen Bio’s Proprietary Targeted T cell Therapy for COVID-19

Under this partnership, experts from BioCentriq and Tevogen Bio will collaborate at BioCentriq’s state-of-the art GMP facilities to produce Tevogen’s proprietary COVID-19 targeted T cells. 

The teams will utilize the processes and technology required to ensure that all quality standards are met in the large scale manufacturing of Tevogen’s clinical grade, allogeneic T-cell therapy.

Read the full press release here.